Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30548561 | 0.82 | ALDH1A1 (0.36) | ALDH1A1LMNAPOLBPKMKDM4E | |
| SCHEMBL1693874 | 0.79 | HPGD (0.44) | ALDH1A1CTSSCTSKLMNAPOLB | |
| SCHEMBL4565411 | 0.77 | CASP2 (0.47) | ALDH1A1LMNAPOLBKDM4EL3MBTL1 | |
| SCHEMBL2035994 | 0.76 | KDM4E (0.39) | ALDH1A1LMNAPOLBPKMKDM4E | |
| SCHEMBL21658063 | 0.76 | ALDH1A1 (0.52) | ALDH1A1CA1LMNAPOLBP2RX7 | |
| SCHEMBL1768368 | 0.76 | SLC1A1 (0.48) | — | |
| SCHEMBL1768364 | 0.76 | SLC1A1 (0.48) | — | |
| Hydrochloric Acid SCHEMBL5707324 | 0.75 | CASP2 (0.45) | ALDH1A1LMNAPOLBKDM4EL3MBTL1 | |
| SCHEMBL30181819 | 0.75 | CNR1 (0.39) | ALDH1A1LMNAPOLBPKMKDM4E | |
| SCHEMBL13407576 | 0.75 | CNR1 (0.39) | ALDH1A1LMNAPOLBKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2559694-A2 | Azaindoles useful as inhibitors of Janus kinases | Vertex Pharmaceuticals, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-2537849-A2 | Azaindoles useful as inhibitors of janus kinases | Vertex Pharmaceuticals, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8163917-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | PYGM, CKMT1A; CKMT1B, SMN1; SMN2 | ALDH1A1 1984/4885CA1 3534/4885CTSS 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.